Allspring Global Investments Holdings LLC Has $323,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Allspring Global Investments Holdings LLC trimmed its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 73.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,837 shares of the specialty pharmaceutical company’s stock after selling 15,894 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in ANI Pharmaceuticals were worth $323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Pacer Advisors Inc. lifted its position in shares of ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after acquiring an additional 565,910 shares during the period. JPMorgan Chase & Co. increased its stake in ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. abrdn plc acquired a new position in ANI Pharmaceuticals during the fourth quarter worth $13,155,000. Bank of Montreal Can bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at $13,043,000. Finally, Mizuho Markets Americas LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at $11,670,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $54.51 on Wednesday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a fifty day moving average of $57.03 and a 200 day moving average of $58.17. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -99.11 and a beta of 0.74. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81.

Insider Activity

In other news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,300 shares of company stock valued at $584,009. 12.70% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.